Cyclacel Pharmaceuticals Inc (CYCC) — Net Asset Quality Index
Cyclacel Pharmaceuticals Inc (CYCC) has a Net Asset Quality Index of 82.5% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $4.40K minus total liabilities of $770.00 yields net assets of $3.63K. A higher index indicates a stronger, lower-leverage balance sheet. Check Cyclacel Pharmaceuticals Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Cyclacel Pharmaceuticals Inc Net Asset Quality Index Over Time (2000–2024)
This chart shows how Cyclacel Pharmaceuticals Inc's Net Asset Quality Index has evolved across 25 annual periods from 2000 to 2024. As of June 2025, the index stands at 82.5%, representing net assets of $3.63K against total assets of $4.40K USD. See CYCC net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Cyclacel Pharmaceuticals Inc (2000–2024)
The table below presents the year-by-year Net Asset Quality Index for Cyclacel Pharmaceuticals Inc from 2000 to 2024, covering 25 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see how much is Cyclacel Pharmaceuticals Inc worth.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | -53.1% | $-2.17 Million | $4.09 Million | $6.27 Million | ▼ -60.0 pp |
| 2023 | 6.9% | $607.00K | $8.80 Million | $8.20 Million | ▼ -66.0 pp |
| 2022 | 72.8% | $20.43 Million | $28.05 Million | $7.62 Million | ▼ -14.5 pp |
| 2021 | 87.4% | $37.69 Million | $43.14 Million | $5.44 Million | ▼ -3.0 pp |
| 2020 | 90.4% | $33.26 Million | $36.80 Million | $3.54 Million | ▲ +14.0 pp |
| 2019 | 76.4% | $11.70 Million | $15.31 Million | $3.61 Million | ▼ -0.6 pp |
| 2018 | 77.0% | $15.27 Million | $19.82 Million | $4.55 Million | ▼ -6.7 pp |
| 2017 | 83.7% | $21.77 Million | $26.00 Million | $4.24 Million | ▲ +11.1 pp |
| 2016 | 72.6% | $14.27 Million | $19.66 Million | $5.39 Million | ▼ -3.5 pp |
| 2015 | 76.1% | $18.84 Million | $24.76 Million | $5.93 Million | ▲ +2.3 pp |
| 2014 | 73.8% | $21.69 Million | $29.39 Million | $7.70 Million | ▼ -5.1 pp |
| 2013 | 78.9% | $28.02 Million | $35.52 Million | $7.50 Million | ▲ +27.1 pp |
| 2012 | 51.8% | $10.02 Million | $19.35 Million | $9.34 Million | ▼ -23.2 pp |
| 2011 | 75.0% | $19.50 Million | $26.00 Million | $6.50 Million | ▼ -4.2 pp |
| 2010 | 79.2% | $24.92 Million | $31.46 Million | $6.54 Million | ▲ +47.1 pp |
| 2009 | 32.1% | $4.64 Million | $14.47 Million | $9.82 Million | ▼ -34.6 pp |
| 2008 | 66.7% | $20.64 Million | $30.96 Million | $10.31 Million | ▼ -9.7 pp |
| 2007 | 76.4% | $57.97 Million | $75.91 Million | $17.94 Million | ▼ -8.8 pp |
| 2006 | 85.2% | $53.92 Million | $63.28 Million | $9.36 Million | ▲ +17.1 pp |
| 2005 | 68.1% | $14.60 Million | $21.45 Million | $6.84 Million | ▼ -11.3 pp |
| 2004 | 79.3% | $44.12 Million | $55.60 Million | $11.48 Million | ▲ +429.9 pp |
| 2003 | -350.5% | $-64.84 Million | $18.50 Million | $83.34 Million | ▼ -127.1 pp |
| 2002 | -223.5% | $-48.12 Million | $21.54 Million | $69.66 Million | ▼ -76.8 pp |
| 2001 | -146.6% | $-36.26 Million | $24.73 Million | $60.99 Million | ▼ -57.5 pp |
| 2000 | -89.1% | $-25.38 Million | $28.48 Million | $53.86 Million | — |